FDA fast tracks Prevail's Parkinson's gene therapy

06:10 EDT 11 Jul 2019 | pharmaphorum

The FDA has fast tracked a gene therapy for a certain form of Parkinson’s Disease from US biotech Prevail Therapeutics. New York-based Prevail is a biotech developing adeno associated virus (AAV)-based gene therapies for patients with neurodegener...

Original Article: FDA fast tracks Prevail's Parkinson's gene therapy


More From BioPortfolio on "FDA fast tracks Prevail's Parkinson's gene therapy"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...